Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer
Genetic Predisposition to Disease
© 2011 Future Medicine Ltd. All rights reserved.Single-agent PARP inhibitors have produced responses in BRCA mutation-associated breast cancer. There are limited data regarding the effects of single-agent PARP inhibitors in sporadic TNBC. Combinations of PARP inhibitors with conventional cytotoxic agents are being studied in both hereditary and sporadic breast cancer. The results of the iniparib Phase III study may not generalize to other PARP inhibitor studies, given differences in patient populations and the activities of the compounds.
part of other document
Digital Object Identifier (DOI)
Additional Document Info